Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (21107)	4/21/1999 8:51:00 PM
From: VLAD	Respond to of 23519

betty, I believe the Janssen royalty situation applies only to China once approved. Funny that they did not mention China during the cc. According to Vivus they expect licensing approval in China in Q3 1999 and it includes a $2M milestone payment from Janssen. Why is it that there is so little data regarding Janssen sales efforts and results in the international countries launched thus far including Mexico, Canada and some of the Pacific rim countries such as South Korea?